ES3012114T3 - Substituted piperidino compounds and related methods of treatment - Google Patents

Substituted piperidino compounds and related methods of treatment Download PDF

Info

Publication number
ES3012114T3
ES3012114T3 ES21854780T ES21854780T ES3012114T3 ES 3012114 T3 ES3012114 T3 ES 3012114T3 ES 21854780 T ES21854780 T ES 21854780T ES 21854780 T ES21854780 T ES 21854780T ES 3012114 T3 ES3012114 T3 ES 3012114T3
Authority
ES
Spain
Prior art keywords
crcrd
alkyl
unsubstituted
halogens
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES21854780T
Other languages
English (en)
Spanish (es)
Inventor
Lewis Pennington
Younggi Choi
Hoan Huynh
Brian Aquila
Ingo Mugge
Yuan Hu
James Woods
Brian Raymer
Jörg Bentzien
Jonathan Lehmann
Srinivasa Karra
Roman A Valiulin
Daljit Matharu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alkermes Inc
Original Assignee
Alkermes Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alkermes Inc filed Critical Alkermes Inc
Application granted granted Critical
Publication of ES3012114T3 publication Critical patent/ES3012114T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/98—Nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Psychiatry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Hydrogenated Pyridines (AREA)
ES21854780T 2020-12-21 2021-12-21 Substituted piperidino compounds and related methods of treatment Active ES3012114T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063128511P 2020-12-21 2020-12-21
PCT/US2021/064484 WO2022140317A1 (en) 2020-12-21 2021-12-21 Substituted piperidino compounds and related methods of treatment

Publications (1)

Publication Number Publication Date
ES3012114T3 true ES3012114T3 (en) 2025-04-08

Family

ID=80218521

Family Applications (1)

Application Number Title Priority Date Filing Date
ES21854780T Active ES3012114T3 (en) 2020-12-21 2021-12-21 Substituted piperidino compounds and related methods of treatment

Country Status (8)

Country Link
US (3) US11760747B2 (cg-RX-API-DMAC10.html)
EP (1) EP4263506B1 (cg-RX-API-DMAC10.html)
JP (1) JP7846113B2 (cg-RX-API-DMAC10.html)
CN (1) CN116670124A (cg-RX-API-DMAC10.html)
AU (1) AU2021409664A1 (cg-RX-API-DMAC10.html)
CA (1) CA3172862A1 (cg-RX-API-DMAC10.html)
ES (1) ES3012114T3 (cg-RX-API-DMAC10.html)
WO (1) WO2022140317A1 (cg-RX-API-DMAC10.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20260083444A (ko) 2019-11-25 2026-06-05 알케르메스,인코포레이티드 치환된 마크로사이클릭 화합물 및 관련 치료 방법
US11760747B2 (en) 2020-12-21 2023-09-19 Alkermes, Inc. Substituted piperidino compounds and related methods of treatment
JP7833486B2 (ja) * 2021-05-26 2026-03-19 アルカーメス,インコーポレイテッド 置換されるカルバメート大環状化合物および関連のある治療方法
WO2023249871A1 (en) * 2022-06-21 2023-12-28 Alkermes, Inc. Substituted pyrrolidinyl and piperidinyl compounds and related methods of treatment
WO2024141660A2 (en) 2022-12-30 2024-07-04 Aexon Labs. Inc. Dihydro-quinazoline, -benzothiazine and -benzoxazine derivatives and use thereof as orexin receptors agonists for treating or preventing neurological diseases
TW202502342A (zh) * 2023-06-02 2025-01-16 日商武田藥品工業股份有限公司 食慾素2受體促效劑用於改善睡眠期間之呼吸功能的用途
CN122374291A (zh) 2023-12-12 2026-07-10 爱杜西亚药品有限公司 作为食欲素受体调节剂的芳基砜及砜酮衍生物
WO2025132542A1 (en) 2023-12-19 2025-06-26 Idorsia Pharmaceuticals Ltd Macrocyclic orexin agonists
TW202547460A (zh) * 2024-04-04 2025-12-16 日商橘生藥品工業股份有限公司 取代磺醯胺化合物

Family Cites Families (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE59010908D1 (de) 1989-09-12 2000-08-10 Hoffmann La Roche TNF-bindende Proteine
US5635599A (en) 1994-04-08 1997-06-03 The United States Of America As Represented By The Department Of Health And Human Services Fusion proteins comprising circularly permuted ligands
WO1999023114A1 (en) 1997-10-31 1999-05-14 Biomira Inc. Muc-1 derivatives and their use in treating cancer-associated muc-1 mucin-induced immunosuppression
AU2903999A (en) 1998-03-12 1999-09-27 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Methods and compositions of chemokine-tumor antigen fusion proteins as cancer vaccines
CA2324205A1 (en) 1998-04-03 1999-10-14 University Of Washington Circularly permuted biotin binding proteins
EP1151012A4 (en) 1998-11-19 2003-01-08 Smithkline Beecham Corp ANTAGONIST ANTIBODIES OF RHAMM
US6428985B1 (en) 1998-12-02 2002-08-06 The Regents Of The University Of Michigan Immunosuppressive structural definition of IL-10
ATE407697T1 (de) 1999-07-13 2008-09-15 Bolder Biotechnology Inc Erythropoietin immunglobulin fusionsproteine
CA2391080A1 (en) 1999-11-12 2001-05-25 Merck Patent Gesellschaft Mit Beschraenkter Haftung Erythropoietin forms with improved properties
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
AU2001231532A1 (en) 2000-02-11 2001-08-20 Maxygen Aps Improved interleukin 10
JP2003530384A (ja) 2000-04-06 2003-10-14 メルク フロスト カナダ アンド カンパニー カテプシンシステインプロテアーゼ阻害薬
SI1724284T1 (sl) 2000-12-07 2009-12-31 Lilly Co Eli Glp-1 fuzijski proteini
HUP0400698A3 (en) 2001-02-06 2006-01-30 Merck Patent Gmbh Modified interleukin-1 receptor antagonist (il-1ra) with reduced immunogenicity
WO2003010201A2 (en) 2001-07-20 2003-02-06 Absorber, Ab Blood group antigen fusion polypeptides and methods of use thereof
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7638323B2 (en) 2002-08-09 2009-12-29 Recopharma Ab Fusion proteins and methods of producing same
WO2004044006A1 (en) 2002-11-14 2004-05-27 Maxygen, Inc. Conjugates of interleukin-10 and polymers
WO2004060911A2 (en) 2002-12-30 2004-07-22 Amgen Inc. Combination therapy with co-stimulatory factors
SI1624891T2 (sl) 2003-05-06 2013-09-30 Biogen Idec Hemophilia Inc. Strjevalni faktor-FC himerni proteini za zdravljenje hemofilije
US7696322B2 (en) 2003-07-28 2010-04-13 Catalent Pharma Solutions, Inc. Fusion antibodies
US20150071948A1 (en) 2003-09-26 2015-03-12 Gregory Alan Lazar Novel immunoglobulin variants
WO2005034863A2 (en) 2003-10-03 2005-04-21 Jarikuma Corporation Countermeasures against malaria
WO2005042573A1 (en) 2003-10-24 2005-05-12 Dana-Farber Cancer Institute, Inc. Modulation of the interaction of muc1 with muc1 ligands
US8454963B2 (en) 2003-11-13 2013-06-04 Musc Foundation For Research Development Tissue targeted complement modulators
US7576183B2 (en) 2003-12-24 2009-08-18 Los Alamos National Security, Llc Structure-based receptor MIMICS targeted against bacterial superantigen toxins
US7851463B2 (en) 2004-10-14 2010-12-14 Abbott Gmbh & Co. Kg Heterocyclic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor
CA2588449A1 (en) 2004-11-24 2006-06-01 Therakine Corporation An implant for intraocular drug delivery
KR20080013853A (ko) 2005-02-23 2008-02-13 사이케노믹스, 인코퍼레이티드 복수매개물질 도파민 수송체 저해물질 및 이와 관련된 용도
US7829679B2 (en) 2005-08-12 2010-11-09 Riken Mucin-type glycoprotein and use thereof
JPWO2007063907A1 (ja) 2005-11-30 2009-05-07 塩野義製薬株式会社 ペプチド糖鎖付加体およびそれを有効成分とする医薬
ATE437889T1 (de) 2005-12-02 2009-08-15 Apceth Gmbh & Co Kg Chemokin-mucin fusionsproteine mit einer gpi- ankerdomäne und deren verwendung als tumor-immun- adjuvanzien oder in der geweberegeneration
WO2008140595A2 (en) 2006-12-01 2008-11-20 President And Fellows Of Harvard College Synthetic trivalent haptens, complexes thereof, and uses therefor
WO2008120093A1 (en) * 2007-04-03 2008-10-09 Pfizer Inc. Sulfonamides and pharmaceutical compositions thereof
WO2008133928A2 (en) 2007-04-27 2008-11-06 The Gi Company, Inc. Mucin glycoproteins and their use for treatment of epithelial lesions and mucin dependent disorders
CA2695374A1 (en) 2007-08-15 2009-02-19 Amunix, Inc. Compositions and methods for modifying properties of biologically active polypeptides
WO2009076236A2 (en) 2007-12-06 2009-06-18 Pain Therapeutics, Inc. Micronized opioid compositions, formulations and dosage forms and methods of making same
US8258163B2 (en) 2008-06-04 2012-09-04 Board Of Regents, The University Of Texas System Small-molecule agonists for type-2 orexin receptor
BRPI0914889A2 (pt) 2008-06-17 2015-11-24 Otsuka Chemical Co Ltd peptídeo glp-1 adicionado de cadeia oligossacarídica
RU2518471C2 (ru) 2008-08-14 2014-06-10 Тиботек Фармасьютикалз Макроциклические индольные производные, применимые в качестве ингибиторов вируса гепатита с
JP2012525415A (ja) 2009-05-01 2012-10-22 オプソテツク・コーポレイシヨン 眼科疾患を処置または予防するための方法
AU2010264095B2 (en) 2009-06-26 2013-07-11 Biogen Ma Inc. Heterocyclic sulfonamides, uses and pharmaceutical compositions thereof
KR20120107122A (ko) 2009-12-22 2012-09-28 노파르티스 아게 치료법에서 사용하기 위한 4가 cd47―항체 불변 영역 융합 단백질
US20130089554A1 (en) 2009-12-29 2013-04-11 Emergent Product Development Seattle, Llc RON Binding Constructs and Methods of Use Thereof
AR080993A1 (es) 2010-04-02 2012-05-30 Hanmi Holdings Co Ltd Formulacion de accion prolongada de interferon beta donde se usa un fragmento de inmunoglobulina
CN101962413B (zh) 2010-09-21 2013-03-13 中国科学技术大学 具有透皮能力和白细胞介素-10活性的融合蛋白及其编码基因与应用
KR101333958B1 (ko) 2010-10-20 2013-11-27 주식회사 한독 인간 인터루킨-1 수용체 길항제-하이브리드 Fc 융합단백질
EP2457579A1 (en) 2010-11-26 2012-05-30 Technische Universität Dresden Covalently linked interleukin -10
TWI622597B (zh) 2011-03-28 2018-05-01 賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
US9527807B2 (en) 2011-04-05 2016-12-27 Takeda Pharmaceutical Company Limited Sulfonamide derivative and use thereof
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
US11492383B2 (en) 2011-06-24 2022-11-08 Stephen D. Gillies Light chain immunoglobulin fusion proteins and methods of use thereof
LT2748201T (lt) 2011-08-23 2018-02-26 Roche Glycart Ag Dvigubai specifinė t ląsteles aktyvinantį antigeną surišanti molekulė
EP2836485B1 (en) 2012-03-17 2018-01-10 Polyphor Ag Conformationally constrained, fully synthetic macrocyclic compounds
US9062120B2 (en) 2012-05-02 2015-06-23 Janssen Biotech, Inc. Binding proteins having tethered light chains
EP2851429B1 (en) 2012-05-18 2019-07-24 Adda Biotech Inc. Protein and protein conjugate for diabetes treatment, and applications thereof
US9156897B2 (en) 2012-06-08 2015-10-13 Alkermes, Inc. Fusion polypeptides comprising an active protein linked to a mucin-domain polypeptide
CN104640561A (zh) 2012-07-23 2015-05-20 酵活有限公司 包含轻链和重链的选择性配对的免疫球蛋白构建体
US9346872B2 (en) 2012-08-08 2016-05-24 Roche Glycart Ag Interleukin-10 fusion proteins
WO2014151910A1 (en) 2013-03-15 2014-09-25 Amgen Inc. Heterodimeric bispecific antibodies
JP2016526014A (ja) 2013-04-24 2016-09-01 アルモ・バイオサイエンシーズ・インコーポレイテッド インターロイキン−10組成物及びその使用
WO2014198880A1 (en) 2013-06-14 2014-12-18 Ferrer Internacional, S.A. 2-(2-aminophenoxy)-3-chloronaphthalene-1,4-dione compounds having orexin 2 receptor agonist activity
EP3027647A4 (en) 2013-07-31 2017-01-04 Amgen Inc. Stabilization of fc-containing polypeptides
US20160250224A1 (en) 2013-09-24 2016-09-01 The Board Of Regents Of The University Of Texas System Orexin-control of bone formation and loss
WO2015073707A1 (en) 2013-11-15 2015-05-21 The Board Of Trustees Of The Leland Stanford Junior University Methods of treating heart failure with agonists of hypocretin receptor 2
SG11201604639YA (en) 2013-12-12 2016-07-28 Univ Tsukuba Sulfonamide derivative or pharmaceutically acceptable acid addition salt thereof
BR112016016658A2 (pt) 2014-02-06 2018-01-23 F. Hoffmann-La Roche Ag proteína de fusão de um anticorpo, polinucleotídeo, vetor, célula hospedeira, composição farmacêutica, métodos para produzir uma proteína de fusão e de tratamento de uma doença em um indivíduo e uso da proteína de fusão
JP6552117B2 (ja) 2014-03-28 2019-07-31 国立大学法人 筑波大学 敗血症の予防治療剤
JP6715239B2 (ja) 2014-09-11 2020-07-01 ヤンセン ファーマシューティカ エヌ.ベー. 置換2−アザ二環式化合物及びオレキシン受容体調節因子としてのその使用
CN104403004B (zh) 2014-11-24 2017-10-13 苏州丁孚靶点生物技术有限公司 抗体‑干扰素异二聚体的制备和用途
EP3233920B1 (en) 2014-12-19 2020-08-26 Alkermes, Inc. Single chain fc fusion proteins
WO2016101119A1 (en) 2014-12-23 2016-06-30 Merck Sharp & Dohme Corp. Fused heteroaryl derivatives as orexin receptor antagonists
WO2016133160A1 (ja) 2015-02-19 2016-08-25 国立大学法人筑波大学 スルホンアミド誘導体またはその薬学的に許容される酸付加塩
CA2989146A1 (en) 2015-06-12 2016-12-15 Board Of Regents, The University Of Texas System Sulfonamide derivative and pharmaceutically acceptable acid addition salt thereof
DK3310784T3 (da) 2015-06-17 2020-11-09 Pfizer Tricykliske forbindelser og deres anvendelse som phosphodiesterasehæmmere
WO2017035354A1 (en) 2015-08-26 2017-03-02 Blueprint Medicines Corporation Compounds and compositions useful for treating disorders related to ntrk
AU2016315878A1 (en) 2015-09-03 2018-03-29 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
US10377770B2 (en) 2015-12-18 2019-08-13 Novartis Ag Tricyclic compounds and compositions as kinase inhibitors
SG11201806429PA (en) 2016-02-04 2018-08-30 Takeda Pharmaceuticals Co Substituted piperidine compound and use thereof
US11291721B2 (en) 2016-03-21 2022-04-05 Marengo Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
WO2018005226A2 (en) 2016-06-22 2018-01-04 Alkermes, Inc. Compositions and methods for modulating il-10 immunostimulatory and anti-inflammatory properties
JP6957598B2 (ja) 2017-03-08 2021-11-02 武田薬品工業株式会社 置換ピロリジン化合物およびその用途
JP7012703B2 (ja) 2017-03-08 2022-02-14 武田薬品工業株式会社 置換ピロリジン化合物およびその用途
US11319286B2 (en) 2017-08-03 2022-05-03 Takeda Pharmaceutical Company Limited Heterocyclic compound and application thereof
US10428023B2 (en) 2017-08-03 2019-10-01 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
CN111132975B (zh) 2017-09-28 2023-05-23 勃林格殷格翰国际有限公司 N-(2,2-二氟乙基)-n-[(嘧啶基氨基)丙基]芳基甲酰胺
JP7170996B2 (ja) 2017-12-12 2022-11-15 国立大学法人 筑波大学 スルホンアミド誘導体またはその薬学的に許容される酸付加塩
WO2019191327A1 (en) 2018-03-27 2019-10-03 Board Of Regents, The University Of Texas System Ox2r compounds
US11655241B2 (en) 2018-06-29 2023-05-23 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
EP3816154B1 (en) 2018-06-29 2025-04-23 Takeda Pharmaceutical Company Limited Heterocyclic compound and application thereof
JP7408569B2 (ja) 2018-12-12 2024-01-05 武田薬品工業株式会社 複素環化合物
JP7379374B2 (ja) 2018-12-12 2023-11-14 武田薬品工業株式会社 複素環化合物
PE20211700A1 (es) 2019-01-31 2021-09-01 Takeda Pharmaceuticals Co Compuesto heterociclico y su uso
WO2020167701A1 (en) 2019-02-13 2020-08-20 Merck Sharp & Dohme Corp. Pyrrolidine orexin receptor agonists
US11098029B2 (en) 2019-02-13 2021-08-24 Merck Sharp & Dohme Corp. 5-alkyl pyrrolidine orexin receptor agonists
EP4010314B1 (en) 2019-08-08 2024-02-28 Merck Sharp & Dohme LLC Heteroaryl pyrrolidine and piperidine orexin receptor agonists
JP2022547604A (ja) 2019-09-13 2022-11-14 武田薬品工業株式会社 過度の眠気の治療のためのオレキシン2受容体アゴニストの使用
CN110642684B (zh) 2019-10-15 2022-07-26 天津师范大学 一类基于联苯芳烃的大环和笼状分子及衍生化合物及其合成方法与应用
KR20260083444A (ko) 2019-11-25 2026-06-05 알케르메스,인코포레이티드 치환된 마크로사이클릭 화합물 및 관련 치료 방법
WO2021106975A1 (ja) 2019-11-27 2021-06-03 武田薬品工業株式会社 複素環化合物
US11352357B2 (en) 2019-11-27 2022-06-07 Sumitomo Dainippon Pharma Co., Ltd. Cycloalkylurea derivative
CA3167050A1 (en) 2020-01-10 2021-07-15 Takeda Pharmaceutical Company Limited A method for enhancing the pharmacokinetics or increasing the plasma concentration of methyl 3-((methylsulfonyl)amino)-2-(((4-phenylcyclohexyl)oxy)methyl)piperidine-1-carboxylate or a salt thereof with an inhibitor of cytochrome p450
CN119235864A (zh) 2020-07-17 2025-01-03 卫材R&D管理有限公司 取代的哌啶化合物及其用途
WO2022040058A1 (en) 2020-08-18 2022-02-24 Merck Sharp & Dohme Corp. Cyclopentapyrrole orexin receptor agonists
US20230365533A1 (en) 2020-08-18 2023-11-16 Merck Sharp & Dohme Llc Bicycloheptane pyrrolidine orexin receptor agonists
CN116635393A (zh) 2020-09-03 2023-08-22 欧瑞夏治疗有限公司 中环或大环苄基取代的杂环衍生物及其作为食欲素-2受体激动剂的用途
US12503475B2 (en) 2020-09-03 2025-12-23 Centessa Pharmaceuticals (Uk) Limited Bicyclic-heterocycle derivatives and their uses as orexin-2 receptor agonists
JP2022064180A (ja) 2020-10-13 2022-04-25 武田薬品工業株式会社 複素環化合物
WO2022094012A1 (en) 2020-11-02 2022-05-05 Merck Sharp & Dohme Corp. Macrocyclic urea orexin receptor agonists
EP4247801A4 (en) 2020-11-23 2024-10-30 Merck Sharp & Dohme LLC 3-AMINO PYRROLIDINE AND MACROCYCLIC PIPERIDINE OREXIN RECEPTOR AGONISTS
US12552767B2 (en) 2020-12-03 2026-02-17 Merck Sharp & Dohme Llc 3-heteroaryl pyrrolidine and piperidine orexin receptor agonists
US12692262B2 (en) 2020-12-16 2026-07-28 Merck Sharp & Dohme Llc Substituted ureas as orexin receptor agonists
US11760747B2 (en) 2020-12-21 2023-09-19 Alkermes, Inc. Substituted piperidino compounds and related methods of treatment
US12006330B2 (en) 2020-12-21 2024-06-11 Alkermes, Inc. Substituted macrocyclic compounds and related methods of treatment
JP7860139B2 (ja) 2021-03-03 2026-05-15 リサーチ トライアングル インスティテュート オレキシン受容体アゴニストとしてのアリールスルホンアミド
WO2022207935A1 (en) 2021-04-02 2022-10-06 Orexia Therapeutics Limited 2-(3-ethynylbenzyl)-substituted heterocycle derivatives as orexin-2 agonists
MX2023012971A (es) 2021-05-03 2024-01-16 Jazz Pharmaceuticals Ireland Ltd Agonistas del receptor de orexina y sus usos.
JPWO2022250108A1 (cg-RX-API-DMAC10.html) 2021-05-26 2022-12-01
EP4359387A1 (en) 2021-06-25 2024-05-01 Jazz Pharmaceuticals Ireland Limited Sulfonamide orexin receptor agonists and uses thereof
WO2023017180A1 (en) 2021-08-13 2023-02-16 Orexia Therapeutics Limited Peptide derivatives and related uses as orexin agonists

Also Published As

Publication number Publication date
US20260078106A1 (en) 2026-03-19
AU2021409664A9 (en) 2024-10-24
JP2023554282A (ja) 2023-12-27
CN116670124A (zh) 2023-08-29
CA3172862A1 (en) 2022-06-30
US20240076283A1 (en) 2024-03-07
US20220194926A1 (en) 2022-06-23
EP4263506B1 (en) 2025-02-05
AU2021409664A1 (en) 2023-05-25
JP7846113B2 (ja) 2026-04-14
EP4263506C0 (en) 2025-02-05
EP4263506A1 (en) 2023-10-25
US11760747B2 (en) 2023-09-19
US12441710B2 (en) 2025-10-14
WO2022140317A1 (en) 2022-06-30

Similar Documents

Publication Publication Date Title
ES3041424T3 (en) Substituted macrocyclic compounds and related methods of treatment
EP4263506B1 (en) Substituted piperidino compounds and related methods of treatment
ES3062687T3 (en) Substituted amide macrocyclic compounds with orexin-2 receptor agonist activity
JP7064512B2 (ja) キナーゼ阻害剤およびその使用
EP3873468A1 (en) 2-amino-n-phenyl-nicotinamides as nav1.8 inhibitors
AU2022281345A1 (en) Substituted fused bicyclic macrocyclic compounds and related methods of treatment
TW200815412A (en) A pharmaceutical combination comprising 3-or 4-monosubstituted phenol and thiophenol derivatives
ES3057101T3 (en) Substituted carbamate macrocyclic compounds and related methods of treatment
TW202132301A (zh) 作為5-羥基色胺受體7 之調節劑之新穎官能化內醯胺及其使用方法
WO2023249872A1 (en) Substituted fused bicyclic compounds and related methods of treatment
CN119730843A (zh) 取代的吡咯烷基和哌啶基化合物以及相关的治疗方法
HK40099265B (en) Substituted piperidino compounds and related methods of treatment
HK40099265A (en) Substituted piperidino compounds and related methods of treatment
HK40108225B (en) Substituted amide macrocyclic compounds with orexin-2 receptor agonist activity
HK40108225A (en) Substituted amide macrocyclic compounds with orexin-2 receptor agonist activity
HK40106635A (en) Substituted carbamate macrocyclic compounds and related methods of treatment
HK40106635B (en) Substituted carbamate macrocyclic compounds and related methods of treatment
EA050101B1 (ru) СОЕДИНЕНИЯ, ТАРГЕТИРУЮЩИЕ МУТАНТ р53